Biologics & Biosimilars

VA Study Tracks Biologics Usage, Finds Dramatic Patient-Age Difference

December 17, 2018 • By Catherine Kolonko

5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval

November 7, 2018 • By Michele B. Kaufman, PharmD, BCGP

Ixekizumab Improves Outcomes of Ankylosing Spondylitis

November 5, 2018 • By Will Boggs, MD

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

October 22, 2018 • By Michele B. Kaufman, PharmD, BCGP

Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA

October 15, 2018 • By Michele B. Kaufman, PharmD, BCGP

California Insurance Commissioner Sues AbbVie over Humira

September 23, 2018

Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection

September 20, 2018 • By Thomas R. Collins

Investigators Assess Infection Risk with RA Biologics

August 29, 2018 • By Thomas R. Collins

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

August 17, 2018 • By Thomas R. Collins

EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray

August 8, 2018 • By Michele B. Kaufman, PharmD, BCGP